Spruce Biosciences (SPRB)
NASDAQ:SPRB
Total Valuation
Spruce Biosciences has a market cap or net worth of $96.72M. The enterprise value is -$7.26M.
Market Cap$96.72M
Enterprise Value-$7.26M
Share Statistics
Spruce Biosciences has 1,372,043 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,372,043
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Spruce Biosciences’s return on equity (ROE) is -0.92 and return on invested capital (ROIC) is -84.42%.
Return on Equity (ROE)-0.92
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-84.42%
Return on Capital Employed (ROCE)-0.85
Revenue Per Employee0.00
Profits Per Employee-1.95M
Employee Count20
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spruce Biosciences is ―. Spruce Biosciences’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio1.57
Price to Fair Value1.57
Price to FCF-2.00
Price to Operating Cash Flow-1.62
PEG Ratio0.04
Income Statement
In the last 12 months, Spruce Biosciences had revenue of 0.00 and earned -38.97M in profits. Earnings per share was -50.83.
Revenue0.00
Gross Profit-21.00K
Operating Income-36.51M
Pretax Income-38.97M
Net Income-38.97M
EBITDA-36.51M
Earnings Per Share (EPS)-50.83
Cash Flow
In the last 12 months, operating cash flow was -33.33M and capital expenditures 0.00, giving a free cash flow of -33.33M billion.
Operating Cash Flow-33.33M
Free Cash Flow-33.33M
Free Cash Flow per Share-24.29
Dividends & Yields
Spruce Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-10.13
52-Week Price Change243.54%
50-Day Moving Average66.53
200-Day Moving Average58.93
Relative Strength Index (RSI)57.59
Average Volume (3m)988.68K
Important Dates
Spruce Biosciences upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateMar 9, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Spruce Biosciences as a current ratio of 5.17, with Debt / Equity ratio of 1.73%
Current Ratio5.17
Quick Ratio5.17
Debt to Market Cap<0.01
Net Debt to EBITDA1.32
Interest Coverage Ratio-405.70
Taxes
In the past 12 months, Spruce Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Spruce Biosciences EV to EBITDA ratio is -0.51, with an EV/FCF ratio of -0.56.
EV to Sales0.00
EV to EBITDA-0.51
EV to Free Cash Flow-0.56
EV to Operating Cash Flow-0.56
Balance Sheet
Spruce Biosciences has $48.91M in cash and marketable securities with $736.00K in debt, giving a net cash position of $48.17M billion.
Cash & Marketable Securities$48.91M
Total Debt$736.00K
Net Cash$48.17M
Net Cash Per Share$35.11
Tangible Book Value Per Share$55.46
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Spruce Biosciences is $217.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$217.67
Price Target Upside208.75% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-90.18%
EPS Growth Forecast-17.93%